Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Cassava Sciences, Inc. SAVA NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
40/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Cassava Sciences, Inc. (SAVA) is a Biotechnology company in the Healthcare sector, currently trading at $1.96. It has a SharesGrow Score of 37/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Net income is $91M (loss), growing at -77.6%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $0 against $74M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 2.23 (strong liquidity). Debt-to-assets is 0%. Total assets: $118M.

Analyst outlook: 8 / 12 analysts rate SAVA as buy (67%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 55/100 (Partial), Income ?/100 (Fail).

SAVA SharesGrow Score Overview

50/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 55/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — SAVA

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
SAVA: +0%/yr revenue is, -77.6%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet SAVA: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 2.23 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
SAVA: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
55/100
Analyst outlook: 8 / 12 analysts rate SAVA as buy (67%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range1.15-4.98
Volume258.48K
Avg Volume (30D)857.77K
Market Cap$94.44M
Beta (1Y)-0.84
Share Statistics
EPS (TTM)-1.88
Shares Outstanding$48.3M
IPO Date2000-07-14
Employees30
CEORichard Jon Barry
Financial Highlights & Ratios
Gross Profit$-936K
EBITDA$-94.45M
Net Income$-90.97M
Operating Income$-95.39M
Total Cash$95.5M
Net Debt$-95.5M
Total Assets$118.36M
Price / Earnings (P/E)-1
Analyst Forecast
Rating ConsensusBuy
Analysts Covering12
Buy 67% Hold 33% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS14817C1071

Price Chart

Track all markets on TradingView
SAVA
Cassava Sciences, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
1.15 52WK RANGE 4.98

People Also View

EXEL
EXEL
Exelixis, Inc.
$45.86
+2.00%
 MDGL
MDGL
Madrigal Pharmaceuticals, Inc.
$524.99
-0.13%
 AXSM
AXSM
Axsome Therapeutics, Inc.
$184.18
+3.28%
 KRYS
KRYS
Krystal Biotech, Inc.
$270.00
+0.97%
 RETA
RETA
Reata Pharmaceuticals, Inc.
$172.36
+0.02%
 TGTX
TGTX
TG Therapeutics, Inc.
$34.56
+2.28%
 VKTX
VKTX
Viking Therapeutics, Inc.
$35.52
+1.46%
 VIR
VIR
Vir Biotechnology, Inc.
$10.05
+7.95%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message